RET
About
Location: 10q11.21
Mappings
Biomarkers
RET is involved in the following curated biomarkers.| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| v::RET | Rearrangement | 7 | 11 |
| RET p.M918T | Somatic Variant | 1 | 1 |
| RET oncogenic variants | Somatic Variant | 1 | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Pralsetinib | |
| Sensitivity (+) | v::RET | Papillary Thyroid Cancer | Pralsetinib | |
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Selpercatinib | |
| Sensitivity (+) | RET oncogenic variants | Medullary Thyroid Cancer | Selpercatinib | |
| Sensitivity (+) | v::RET | Anaplastic Thyroid Cancer | Selpercatinib | |
| Sensitivity (+) | v::RET | Any solid tumor | Selpercatinib | |
| Sensitivity (+) | v::RET | Medullary Thyroid Cancer | Vandetanib | |
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Pralsetinib | |
| Sensitivity (+) | v::RET | Non-Small Cell Lung Cancer | Selpercatinib | |
| Sensitivity (+) | v::RET | Papillary Thyroid Cancer | Selpercatinib | |
| Sensitivity (+) | RET p.M918T | Medullary Thyroid Cancer | Selpercatinib | |
| Sensitivity (+) | v::RET | Any solid tumor | Selpercatinib | |
| Sensitivity (+) | v::RET | Medullary Thyroid Cancer | Vandetanib |